Replicor to Make Three Presentations at EASL 2016

[sorte]

NEW YORK, April 4, 2016 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that it will present three abstracts at the EASL 2016 annual meeting to be held April 13-26, 2017 in Barcelona, Spain.
These presentations will disclose updated clinical, pre-clinical and mechanistic data on the activity of NAPs against chronic hepatitis B and hepatitis D infection:
·        Updated clinical data from the ongoing REP 301 study assessing the safety and efficacy of REP 2139-Ca combined with pegylated interferon in patients with hepatitis B / hepatitis D co-infection (poster FRI-105).
·        In vivo antiviral activity of REP 2139-Ca combined with tenofovir disoproxil fumarate and entecavir (poster THU-177).
·        Immunostimulatory properties of REP 2139 and other NAP compounds (poster THU-204).
Replicor’s presentations will be available on the company’s website at the end of the conference at www.replicor.com/science/conference-presentations.  For the 2016 EASL Meeting: http://ilc-congress.eu/.

[Jatashankar]

its like dream. a cure for hep b